Visus’ BRIMOCHOL PF meets primary endpoints in phase 3 trial in presbyopia
The late-stage trial compared the investigational ophthalmic solution against carbachol monotherapy topical ophthalmic solution as well as brimonidine…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 May 23
The late-stage trial compared the investigational ophthalmic solution against carbachol monotherapy topical ophthalmic solution as well as brimonidine…
05 May 23
Investment of nearly $50 million behind product, process and packaging development for consumer-favorite snacks like OREO, Ritz and…
05 May 23
Today Walkers has announced a new ambition that by 2025, half of our snacks sales will come from…
05 May 23
Nestlé has officially inaugurated the Institute of Agricultural Sciences to help advance sustainable food systems by delivering science-based…
05 May 23
Purpose-built by Charter Hall, the new Equipment Services and Point-of-Sale facility at Richlands will drive business efficiencies and…
04 May 23
The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy…
04 May 23
In the late-stage trial, the investigational amyloid plaque targeting therapy significantly decelerated cognitive and functional decline in patients…
03 May 23
Janssen will obtain an exclusive license to develop and commercialise CBMG’s C-CAR039 and C-CAR066 in geographic territories outside…
03 May 23
Under the agreement, Lundbeck will have access to Alloy Therapeutics’ antibody discovery services as well as its SeqImmune…
02 May 23
The US FDA accepted BMS’ supplemental Biologics License Application (sBLA) and granted Priority Review for Reblozyl, while the…